Institutional members access full text with Ovid®

Share this article on:

Viagra, Methamphetamine, and HIV Risk: Results From a Probability Sample of MSM, San Francisco

Spindler, Hilary H. MPH*; Scheer, Susan PhD, MPH*; Chen, Sanny Y. MS*; Klausner, Jeffrey D. MD, MPH*†; Katz, Mitchell H. MD*; Valleroy, Linda A. PhD; Schwarcz, Sandra K. MD, MPH*†

Sexually Transmitted Diseases: August 2007 - Volume 34 - Issue 8 - p 586-591
doi: 10.1097/01.olq.0000258339.17325.93
Article

Objectives: To determine the prevalence and factors of Viagra use in combination with crystal methamphetamine and its association with HIV risk behavior in a probability sample of men who have sex with men (MSM).

Study Design: A cross-sectional, random-digit dial telephone survey of MSM in San Francisco conducted between June 2002 and January 2003.

Results: Of the 1976 MSM, 13.5% used Viagra alone, 7.1% used methamphetamine without Viagra, 9.6% used Viagra with a mood-altering substance (excluding methamphetamine), and 5.1% used Viagra with methamphetamine. Of the MSM using Viagra with methamphetamine, 57% were HIV-infected and 24% of these men reported serodiscordant unprotected insertive intercourse. Viagra used with methamphetamine was independently associated with a higher risk of serodiscordant unprotected insertive intercourse, serodiscordant unprotected receptive intercourse, and a recent diagnosis of a sexually transmitted disease.

Conclusion: MSM who use Viagra with crystal methamphetamine have high prevalence rates of HIV and engage in HIV risk behaviors.

MSM who use Viagra with crystal methamphetamine have high prevalence rates of HIV and engage in HIV risk behaviors.

From the *San Francisco Department of Public Health, San Francisco, California; †University of California, San Francisco, California; and ‡Centers for Disease Control and Prevention, Atlanta, Georgia

This study was supported through the Centers for Disease Control and Prevention cooperative agreement number U62/CCU906255.

The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention.

Portions of this manuscript were presented at “PDE-5 Inhibition and HIV Risk: Current Concepts And Controversies” at the Bolger Center, Potomac, Maryland, September 26–27, 2005.

Correspondence: Hilary Spindler, 50 Beale St, Suite 1200, San Francisco, CA 94105. E-mail: hilary.spindler@gmail.com.

Received for publication July 26, 2006, and accepted November 27, 2006.

© Copyright 2007 American Sexually Transmitted Diseases Association